Overall, these orthogonal approaches indicate uterine tumors with ACTG1 gains have repressed IFN-γ and lymphocyte infiltration, which suggests these tumors may exhibit differential responses towards innate immunity or even immunotherapies. This evidence concerns the gene ACTG1 and tumor of uterus.